September 13, 2021 Off

USFDA accepts Novartis’ tislelizumab for people with esophageal cancer

By Dino Mustafić

Novartis got an acceptance by the US Food and Drug Administration (FDA) for its Biologics License Application (BLA) for anti-PD-1 immune checkpoint inhibitor tislelizumab for the treatment of unresectable recurrent locally advanced or metastatic esophageal squamous cell carcinoma (ESCC) in people who had received prior systemic therapy.